261. Tangier disease Clinical trials / Disease details
Clinical trial : 1 / Drugs : 2 - (DrugBank : 1) / Drug target gene : 0 - Drug target pathway : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01782027 (ClinicalTrials.gov) | October 2012 | 30/1/2013 | Mendelian Reverse Cholesterol Transport Study | A Validation Study Evaluating the Use of 3H-Cholesterol Bound to Albumin as a Method to Assess Reverse Cholesterol Transport in Subjects With Monogenic Diseases Affecting HDL Metabolism | Cholesterol, HDL;Lipid Metabolism, Inborn Errors;Tangier Disease;LCAT Deficiency;Cholesteryl Ester Transfer Protein (CETP) Deficiency | Drug: 3H-cholesterol bound to albumin | University of Pennsylvania | NULL | Suspended | 18 Years | 75 Years | All | 30 | N/A | United States |